Welcome to our dedicated page for Paysign SEC filings (Ticker: PAYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Paysign, Inc. (PAYS) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As an SEC registrant under file number 001-38623, Paysign submits current reports on Form 8-K and other required filings that document financial results, material events and corporate governance matters related to its fintech and healthcare-focused operations.
Recent Form 8-K filings include items under Results of Operations and Financial Condition, where Paysign furnishes press releases detailing quarterly financial results. These exhibits describe total revenues, the breakdown between plasma revenue, pharma patient affordability revenue and other revenue, as well as information on gross profit, operating expenses, EBITDA, Adjusted EBITDA and related non-GAAP metrics. Such filings help readers understand how the company’s prepaid card programs, patient affordability offerings, donor compensation solutions and payment processing activities contribute to its financial performance.
Other 8-K filings address Regulation FD Disclosure items, including information about stockholder derivative actions and proposed settlements. These documents outline the nature of the litigation, the terms of stipulations and agreements of settlement, and the anticipated corporate governance reforms and procedures that the company has agreed to adopt, subject to court approval. Exhibits may include notices of pendency and proposed settlement and related press releases.
Through Stock Titan, users can monitor Paysign’s real-time updates from EDGAR and review filings that reference key exhibits, such as earnings press releases and settlement documentation. The filings page is a resource for examining how Paysign reports on its plasma and pharma patient affordability businesses, restricted cash for customer card funding and pharmaceutical claim reimbursements, and other material developments affecting its fintech healthcare ecosystem.
AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting important sections related to revenue composition, cost structure, litigation, governance changes and other disclosures, helping users interpret complex regulatory documents more efficiently.
Paysign, Inc. reported strong Q3 2025 results. Revenue was $21,596,478 (up 41.6% year over year), led by pharma programs at $7,920,604 (up 141.9%) and plasma at $12,860,478 (up 12.4%). Gross margin improved to 56.3%.
Net income was $2,215,135 and diluted EPS was $0.04. Operating income rose to $1,581,951, while interest income contributed $663,666. The effective tax rate was 1.36%. Year-to-date, revenue reached $59,272,980 (up 38.6%) and net income was $6,188,996 (up 153.3%), reflecting higher pharma activity and added plasma centers.
Cash was $7,529,047 with total cash and restricted cash of $118,551,886 at period end. Accounts receivable increased to $49,644,417. The company closed the Gamma Innovation acquisition on March 19, 2025 for $15,558,637, adding $11,071,000 of identifiable intangibles and $4,487,637 of goodwill. Shares outstanding were 55,042,888 as of November 6, 2025.
Paysign, Inc. furnished an 8-K under Item 2.02 to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. Under General Instruction B-2, this information is furnished and not deemed filed under the Exchange Act. Paysign’s common stock trades on Nasdaq under ticker PAYS.
Paysign, Inc. insider Robert Strobo acquired 100,000 shares of restricted common stock on 05/07/2025 at a reported price of $0.00, increasing his beneficial ownership to 347,290 shares. The shares are restricted and will vest in three equal installments: one-third on May 27, 2026, one-third on May 24, 2027, and the final third on May 26, 2028, subject to Strobo's continued service to the company through each vesting date.
The Form 4 was signed by Robert Strobo on 09/26/2025 and identifies his role as Chief Legal Officer and as an officer reporting person. No derivative transactions, dispositions, exercise prices, or additional cash consideration are reported in this filing.
Joan M. Herman, who serves as Executive Vice President, Operations and a director of Paysign, Inc. (PAYS), reported an equity grant on Form 4. On 05/07/2025 she acquired 16,667 shares of restricted common stock at a reported price of $0.000. Following the grant, the filing shows she beneficially owns 838,250 shares in total. The restricted shares vest in three equal installments: 1/3 on May 13, 2026, 1/3 on May 13, 2027 and 1/3 on May 13, 2028, subject to continued service. The Form 4 is signed by Ms. Herman on 09/26/2025.
Paysign, Inc. reported a Form 4 showing that Jeffery Bradford Baker, the company's Chief Financial Officer and a director, was granted 100,000 shares of restricted common stock on 05/07/2025 at a reported price of $0.000. Following the grant, Baker beneficially owns 352,273 shares. The restricted shares vest in three equal installments: one-third on May 29, 2026, one-third on May 20, 2027, and one-third on May 30, 2028, subject to continued service. The Form 4 is signed by Baker on 09/26/2025.
Paysign, Inc. has moved toward resolving several previously reported stockholder derivative lawsuits by entering into a Stipulation and Agreement of Settlement as a nominal defendant. The cases, all in the U.S. District Court for the District of Nevada, alleged securities law violations and related fiduciary claims, and are collectively referred to as the Derivative Actions.
On August 28, 2025, the Court set a final approval hearing for November 14, 2025 at 1:00 p.m. to decide whether the proposed settlement is fair, reasonable, and adequate and to consider any objections. If the Court grants final approval, the settlement will release all claims arising from the Derivative Actions, dismiss the cases with prejudice, and require Paysign to adopt and maintain specified corporate governance reforms. The settlement does not include any admission of fault or wrongdoing, and Paysign states that resolving the claims now is in the best interests of the company and its stockholders given the costs and risks of continued litigation.
Key results (Q2 2025): Total revenues $19,078,353; gross profit $11,755,165; net income $1,387,761; gross margin 61.6%.
Six months YTD: Revenues $37,676,502; net income $3,973,861; gross margin 62.2%. Total assets $193,896,201; total liabilities $151,688,242; cash and restricted cash $113,913,123.
Drivers and transactions: Revenue growth driven by pharma industry (+$5,079,005; +189.9% Q2; +$11,309,014; +223.3% YTD). Plasma revenue declined (-4.7% Q2; -6.9% YTD). On March 19, 2025 Paysign acquired Gamma Innovation LLC: preliminary purchase consideration $15,558,637; identifiable intangible assets $11,071,000; goodwill $4,487,637; earn-out contingent consideration revised to $990,000.
Paysign, Inc. (PAYS) – Form 4 insider activity
Chief Legal Officer Robert Strobo reported two transactions. On 31 Jul 2025 he vested/exercised 64,000 restricted shares (Code “M”) at $0, lifting his direct holding to 273,811 shares. On 4 Aug 2025 he sold 26,521 common shares in the open market (Code “S”) at a weighted-average price of $7.0851 (range $6.9976–$7.1530). Post-sale he directly owns 247,290 shares.
The stock grant vests 20 % annually from 31 Jul 2022 through 31 Jul 2027. Derivative table shows 128,000 shares still underlying outstanding awards.
- Net change: +37,479 shares retained.
- Portion sold: ≈41 % of newly vested shares.
No earnings, guidance, or other financial disclosures are included.